ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. (Nasdaq: LSPR) is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC business combination and operates in the life sciences sector with a pipeline focused on kidney disease and neuroinflammation. The company filed an S-1/A registration statement amendment with the SEC on December 6, 2023, under accession number 0001493152-23-043877, reflecting ongoing post-merger registration activity. ZyVersa's lead programs advance two platform technologies targeting cholesterol efflux and inflammasome inhibition, with key indications including focal segmental glomerulosclerosis. Investors and analysts seeking complete filing history, SPAC structure details, and deal timelines for LSPR can access the full dataset by signing up on SpacDesk.